Osimertinib Clinical Trials
46 recruitingDrug
Phase 222Phase 115Phase 310Not Applicable1
Showing 1–20 of 46 trials
Recruiting
Phase 1Phase 2
Study of Oral EGFR Inhibitor DZD6008 Combined With Sunvozertinib in Patients Who Have Advanced NSCLC With EGFR Mutations (TIAN-SHAN8)
Non-small Cell Lung Cancer
Dizal (Jiangsu) Pharmaceutical Co., Ltd.160 enrolled17 locationsNCT07079475
Recruiting
Phase 2
A ctDNA-guided Phase II Trial of Osimertinib in Combination With Sacituzumab Tirumotecan in EGFR-mutated Advanced NSCLC Patients With Positive ctDNA After lead-in Osimertinib Monotherapy
Non-small Cell Lung Cancer
Guangdong Association of Clinical Trials120 enrolled4 locationsNCT07375316
Recruiting
Phase 2
Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change
Recurrent Lung Non-Small Cell CarcinomaAdvanced Lung Non-Small Cell CarcinomaStage IIIB Lung Non-Small Cell Cancer AJCC v7+1 more
National Cancer Institute (NCI)46 enrolled344 locationsNCT03191149
Recruiting
Phase 3
Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer
Stage IIIB Lung Cancer AJCC v8Stage IV Lung Cancer AJCC v8Advanced Lung Non-Squamous Non-Small Cell Carcinoma+2 more
National Cancer Institute (NCI)300 enrolled604 locationsNCT04181060
Recruiting
Phase 3
A Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Metastatic Non Small Cell Lung Cancer
AstraZeneca744 enrolled303 locationsNCT06417814
Recruiting
Phase 3
EGFR-mutated Lung Cancer in Randomized Investigator-Initiated Study
Non-small Cell Lung Cancer
Region Skane200 enrolled1 locationNCT06486142
Recruiting
Phase 1
First in Human Study of AZD9592 in Solid Tumors
Carcinoma, Non-Small Cell LungColorectal NeoplasmsHead and Neck Neoplasms+1 more
AstraZeneca403 enrolled51 locationsNCT05647122
Recruiting
Phase 2
Phase II Study of Sacituzumab Tirumotecan in Combination With Osimertinib or Sacituzumab Tirumotecan for Neoadjuvant Treatment in Patients With Resectable Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer
Non-small Cell Lung Cancer
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.60 enrolled1 locationNCT07329322
Recruiting
Phase 1Phase 2
A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors
Breast CancerLung Cancer
Bristol-Myers Squibb416 enrolled64 locationsNCT06618287
Recruiting
Phase 2
Biologically Guided Radiation Therapy (BgRT) and Stereotactic Body Radiation Therapy (SBRT) to Tyrosine Kinase Inhibitor in Oligoprogressive Oncogenic Positive Non-Small Cell Lung Carcinoma
Stage IV Lung Cancer AJCC v8Lung Non-Small Cell Carcinoma
City of Hope Medical Center32 enrolled2 locationsNCT06014827
Recruiting
Phase 3
A Study of SKB264 in Combination With Osimertinib Versus Osimertinib in Patients With Epidermal Growth Factor Receptor (EGFR) Mutations, Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
Non-small Cell Lung Cancer
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.420 enrolled2 locationsNCT06670196
Recruiting
Phase 3
Phase III, Open-label Study of First-line Osimertinib With or Without Datopotamab Deruxtecan for EGFRm Locally Advanced or Metastatic Non-small Cell Lung Cancer
Non-small Cell Lung Cancer
AstraZeneca582 enrolled166 locationsNCT06350097
Recruiting
Phase 2
Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)
Stage IV Lung Cancer AJCC v8Recurrent Lung Non-Small Cell Carcinoma
SWOG Cancer Research Network66 enrolled454 locationsNCT05642572
Recruiting
Phase 1
Study of Osimertinib With Carotuximab in Advanced, EGFR-mutated Non-Small Cell Lung Cancer
Lung CancerNon-small Cell Lung Cancer
Karen Reckamp, MD, MS60 enrolled5 locationsNCT05401110
Recruiting
Phase 3
Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung Cancer
Locally Advanced Lung Non-Small Cell CarcinomaStage III Lung Cancer AJCC v8Stage IIB Lung Cancer AJCC v8
NRG Oncology474 enrolled471 locationsNCT05624996
Recruiting
Investigation of REcurrence Mechanisms to Adjuvant osimertINib in Radically Resected EGFR-mutated NSCLC Patients
EGFR-mutated NSCLC
Gruppo Oncologico Italiano di Ricerca Clinica100 enrolled25 locationsNCT07363252
Recruiting
Phase 1Phase 2
A Study of Ivonescimab in Combination With Dato-DXd or Osimertinib in People With Non-Small Cell Lung Cancer
Non-small Cell Lung Cancer
Memorial Sloan Kettering Cancer Center66 enrolled7 locationsNCT07535437
Recruiting
Phase 3
A Study of BL-B01D1 in Combination With Osimertinib Versus Osimertinib as First-Line Treatment in Patients With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer(PANKU-Lung04)
Non-small Cell Lung Cancer
Sichuan Baili Pharmaceutical Co., Ltd.720 enrolled1 locationNCT06838273
Recruiting
Phase 2
Telisotuzumab Vedotin and Osimertinib for the Treatment of Progressive, Incurable, Non Small Cell Lung Cancer
Lung Non-Small Cell Carcinoma
Jonsson Comprehensive Cancer Center60 enrolled1 locationNCT07323641
Recruiting
Phase 1
Clinical Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 Alone and in Combinations in Patients With Advanced Non-small Cell Lung Cancer
Non-small Cell Lung Cancer
BioNTech SE320 enrolled44 locationsNCT05142189